Zepbound® and stomach pain

What the abdominal pain row actually counts

Zepbound®’s US label builds its side-effect table from SURMOUNT-1, in adults without diabetes, and SURMOUNT-2, in adults with type 2 diabetes: 2,519 people treated for up to 72 weeks. A reaction is listed if at least 2% on Zepbound® had it and it was more frequent than on placebo. ^[1] One detail is easy to miss: only SURMOUNT-1 tested 5 mg, so that column rests on a single trial, while 10 mg and 15 mg draw on both. ^[3]

Under “abdominal pain” the US footnote gathers abdominal discomfort, abdominal pain, lower and upper abdominal pain and abdominal tenderness. ^[1] The Canadian monograph prints the same trials with patient counts, a lower 1% entry bar and one extra term, gastrointestinal pain. ^[3] There is no Zepbound® entry in the European Union; its product information covers tirzepatide under the name Mounjaro®, and there abdominal pain is rated very common in the weight-management and sleep apnoea trials. ^[4]

When in treatment it tends to appear

The label gives no timeline for abdominal pain on its own. It does say that most nausea, vomiting and diarrhea arrived while the dose was being stepped up and then eased, and that people who stopped Zepbound® because of side effects mostly did so in the first few months, for digestive reasons. ^[1] Across the two trials, 1.9%, 3.3% and 4.3% stopped because of digestive reactions, against 0.5% on placebo. ^[1]

The longest view comes from SURMOUNT-1’s three-year analysis of 1,032 people with obesity and prediabetes treated for 176 weeks: digestive complaints were mostly mild or moderate and came mainly in the first 20 weeks, during dose escalation. ^[5] The European information, describing SURMOUNT-1, rates 60.8% of digestive reactions mild and 34.6% moderate. ^[4]

Why it may hurt: three layers of evidence

• What the label supports. Tirzepatide delays stomach emptying; the delay is greatest after the first dose and shrinks over time. ^[1] The table that lists abdominal pain also lists indigestion, constipation, wind and a swollen abdomen, any of which can be felt as pain. ^[1] Separately, the label ties gallbladder events to weight reduction itself. ^[1]
• Suggested, not measured. A 2024 review in the Journal of Clinical Endocrinology & Metabolism notes that GLP-1 medicines and tirzepatide slow both the stomach and the small intestine, and that this braking effect fades with prolonged treatment. ^[8] That fits the early timing in the trials, but none of these sources measured gut movement in people who reported pain, so it remains an explanation rather than a finding.
• General medical background. Cleveland Clinic points out that “stomach” pain can come from any organ in the abdomen, from the abdominal wall, or from the chest, pelvis or back, and that how much it hurts does not reliably match how serious the cause is. ^[9]

A map of pain patterns

Clinicians divide the belly into four quadrants because location narrows down the organ involved, Cleveland Clinic explains. ^[9] Read against Zepbound®’s product information, five patterns stand out.

• Upper abdomen, boring through to the back, severe and lasting. This is the label’s picture of possible acute pancreatitis, with or without nausea or vomiting. ^[1] NIDDK adds that it can begin slowly or suddenly, may last several days and can bring fever, a fast heartbeat or a swollen, tender belly. ^[10]
• Upper right, often in the evening or at night after a heavy meal, lasting hours. NIDDK calls this a gallbladder attack. ^[11] Canada’s patient information says gallbladder pain can also be felt in the right shoulder or between the shoulder blades, and can come on suddenly and build. ^[3]
• Burning or fullness high in the middle after eating. Indigestion and reflux are separate, common rows in the same table, ^[1] and Cleveland Clinic lists indigestion and chronic reflux among usual causes of pain after meals. ^[9]
• Crampy pain with bloating, gas, constipation or vomiting. Canada’s patient information describes ileus, a loss of muscle movement in the bowel, in these terms, together with loss of appetite. ^[3] The US label lists ileus and intestinal obstruction among reports received after approval. ^[1]
• Pain with severe nausea and vomiting, plus belching or bloating that will not let up. Canada gives this as the picture of gastroparesis, or slow stomach emptying, and places it, like ileus, among effects for which you stop the medicine and get immediate help. ^[3]

How often the serious causes turned up

In the weight trials, pancreatitis confirmed by an adjudication committee occurred in 0.2% of people on Zepbound® and 0.2% on placebo (0.14 and 0.15 per 100 years of exposure). ^[1] In the two sleep apnoea trials the rate was 0.84 per 100 years on Zepbound® and zero on placebo. ^[1] Gallstones were reported in 1.1% against 1%, gallbladder inflammation in 0.7% against 0.2%, and gallbladder removal in 0.2% against none. ^[1] Severe digestive reactions of any kind affected 1.7%, 2.5% and 3.1% on the three doses, against 1% on placebo; Canada pools them at 2.7% against 1.2%. ^[1][3]

Outside the label, a 2025 meta-analysis of 13 randomised trials in 26,894 people with obesity but no diabetes found more digestive side effects on tirzepatide than on placebo (risk ratio 2.94), mostly mild, but no significant rise in gallbladder, liver or pancreas events. ^[6] Reports to the FDA add a different kind of signal: a 2026 analysis of 67,305 tirzepatide cases linked pancreatitis, impaired stomach emptying, dehydration and gallstones with serious outcomes; such reports cannot prove cause. ^[7]

Causes that have nothing to do with the injection

Cleveland Clinic says most abdominal pain is short-lived and not serious. After meals, indigestion, gas, constipation, diarrhea, food intolerance and food poisoning are typical; stomach flu, a peptic ulcer or a urinary infection can also hurt, as can menstrual cramps. ^[9]

More serious causes, by location, include gallstones and kidney stones on the upper right, gastritis and stomach ulcer on the upper left, and diverticulitis or appendicitis lower down. ^[9] NIDDK warns that gallstone pain can resemble appendicitis, ulcers, pancreatitis and reflux disease, which is why an examination matters. ^[11]

What may ease milder pain

For a stomachache that seems related to digestion, Cleveland Clinic describes resting the bowel with plain, easy-to-digest foods, drinking enough fluid and using warmth from a hot water bottle or a bath; for prevention, it lists smaller and more frequent meals, enough fibre, regular activity and less alcohol. ^[9] The Zepbound® Medication Guide separately asks you to drink fluids to lower the chance of dehydration when nausea, vomiting or diarrhea occur. ^[2]

Cleveland Clinic also names acetaminophen (paracetamol) as an over-the-counter pain reliever. ^[9] Canada’s monograph tested it alongside tirzepatide: after a first 5 mg dose its peak level fell by about 55% and arrived an hour later, the effect faded with repeated doses, total exposure was unchanged, and no acetaminophen dose change is considered necessary. ^[3] Ask your pharmacist or prescriber whether a pain reliever suits you; Zepbound® can also change how tablets are absorbed. ^[1]

If the pain leads to a scope, scan or surgery

Persistent abdominal pain sometimes ends in an endoscopy or an operation such as gallbladder removal. Because Zepbound® slows stomach emptying, section 5.9 of the label describes rare reports of stomach contents entering the lungs under general anaesthesia or deep sedation in people on GLP-1 medicines, despite fasting beforehand. ^[1] The 2024 review found retained stomach contents more often at endoscopy in people on these medicines. ^[8]

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help